Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (154)
  2. Journal Article (124)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (294)
  2. Genitourinary Oncology Service (294)
  3. Solid Tumor Oncology Division (294)
  4. Weinberg Fellows (108)
  5. Human Oncology and Pathogenesis Program (106)
  6. Surgery (106)

More Groups

People
  1. Robert Motzer (178)
  2. Abraham Hakimi (97)
  3. Darren Feldman (81)
  4. Chung-Han Lee (75)
  5. Maria Carlo (68)
  6. Ritesh Kotecha (65)

More People

Years
  1. 2025 (12)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (120)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (124)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (19)
  6. Biomed Central Ltd (15)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)
    Meeting Abstract

    Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors
    Meeting Abstract

    Shah, A. Y.; Kotecha, R.; Lemke, E.; Chandramohan, A.; Chaim, J.; Msaouel, P.; Xiao, L.; Gao, J.; Campbell, M. T.; Zurita, A. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study
    Meeting Abstract

    Meric-Bernstam, F.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Tannir, N. M.; Owonikoko, T. K.; Haas, N. B.; Voss, M. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Rates of occult brain metastases in patients (pts) with advanced renal cell carcinoma (RCC): A cohort study from patients treated across 22 clinical trials
    Meeting Abstract

    Kotecha, R.; Redzematovic, A.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Genomic biomarkers of response to nivolumab/ipilimumab (nivo/ipi) and nivolumab (nivo) monotherapy in 108 patients with advanced renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Di Natale, R. G.; Chowell, D.; Makarov, V.; Redzematovic, A.; Murray, S. J.; Carlo, M. I.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Alterations in DNA damage repair (DDR) genes and outcomes to systemic therapy in 225 immune-oncology (10) versus tyrosine kinase inhibitor (TKI) treated metastatic clear cell renal cell carcinoma (mccRCC) patients (pts)
    Meeting Abstract

    Ged, Y.; Chaim, J.; Knezevic, A.; Carlo, M. I.; Foster, A.; Feldman, D. R.; Teo, M. Y.; Riaz, N.; Lee, C. H.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • The impact of PBRM1 mutations on overall survival in greater than 2,100 patients treated with immune checkpoint blockade (ICB)
    Meeting Abstract

    Hakimi, A. A.; Ged, Y.; Flynn, J.; Hoen, D. R.; Di Natale, R. G.; Blum, K. A.; Makarov, V.; Kuo, F.; Carlo, M. I.; Lee, C. H.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Molecular screening of patients with FGFR alterations for phase 1 (ph1) study with the selective FGFR inhibitor Debio 1347
    Meeting Abstract

    Iafrate, A. J.; Borger, D. R.; Vivancos, A.; Voss, M.; Cleary, J.; Meric-Bernstam, F.; Tabernero, J.; Flaherty, K.; Ishii, N.; Brichory, F.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Systemic therapy for metastatic renal cell carcinoma-is timing everything?
    Editorial

    Kotecha, R. R.; Voss, M. H.
    Annals of Translational Medicine (2019)

    Fulltext@MSK | Save